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a b s t r a c t
Mayaro virus (MAYV) is an arbovirus linked to several sporadic outbreaks of a highly debilitating febrile
illness in many regions of South America. MAYV is on the verge of urbanization from the Amazon region
and no effective antiviral intervention is available against human infections. Our aim was to investigate
whether bovine lactoferrin (bLf), an iron-binding glycoprotein, could hinder MAYV infection. We show
that bLf promotes a strong inhibition of virus infection with no cytotoxic effects. Monitoring the effect of
bLf on different stages of infection, we observed that virus entry into the cell is the heavily compromised
event. Moreover, we found that binding of bLf to the cell is highly dependent on the sulfation of
glycosaminoglycans, suggesting that bLf impairs virus entry by blocking these molecules. Our ﬁndings
highlight the antiviral potential of bLf and reveal an effective strategy against one of the major emerging
human pathogens in the neotropics.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Arbovirus infections are a major public health problem world-
wide, affecting countless individuals each year. MAYV, a member
of the genus Alphavirus in the family Togaviridae (Casals and
Whitman, 1957), has gained a prominent position in recent years
among those arboviruses linked to human infections. Since the
ﬁrst isolation of the virus in Trinidad in 1954 (Anderson et al.,
1957), several cases of Mayaro fever have been described in the
Amazonian rain forest regions of South America, notably in North-
ern Brazil (Pinheiro et al., 1981). Although Mayaro fever is highly
debilitating and its urbanization from the Amazon region is
imminent (Mourão et al., 2012), the disease is largely neglected,
and many details of the replication cycle of the virus remain
unclear. As for other arbovirus diseases, no effective antiviral
intervention is available for cases of Mayaro fever.
However, a natural macromolecule may provide a potential
alternative. Lactoferrin is an iron-binding globular glycoprotein
with a molecular mass of approximately 80 kDa that belongs to
the transferrin family of proteins (Metz-Boutigue et al., 1984).
Found predominantly in milk and various mucosal secretions,
such as tears, saliva and seminal and vaginal ﬂuids, lactoferrin
plays an important role in the primary defense against a broad
spectrum of pathogenic microorganisms, including Gram-
positive and Gram-negative bacteria, fungi and many enveloped
and non-enveloped viruses (Jenssen and Hancock, 2009). This
intrinsic antimicrobial activity of lactoferrin makes this protein
an interesting candidate for therapeutic applications during
microbial infections. Indeed, lactoferrin is currently produced
on a large scale from the form found in bovine milk (bLf), and
using this commercially available material has advanced scien-
tiﬁc research on lactoferrin applications from basic studies to
clinical trials (Tomita et al., 2009).
The aim of this study was to evaluate the antiviral potential of
bLf during MAYV infection. Using plaque assays and imaging cells
infected with ﬂuorescently labeled virus particles, we tested the
ability of bLf to inhibit MAYV infection in Vero cells and attempted
to determine the stage of the infectious cycle at which the protein
exerts its antiviral effects. Our results demonstrate that bLf
interacts with cell-surface GAGs to inhibit the early events of virus
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infection, suggesting that bLf is a potential candidate for the
prevention and/or treatment of human MAYV infections.
Results
BLf toxicity in Vero cells
As a measure of the bLf toxicity in the cell lineage used for
experimental infections, we tested the effect of different concentra-
tions of the protein on the viability of Vero cells. For this experiment,
the cells were incubated with different concentrations of bLf for 48 h
at 37 1C and then assayed for viability. Under these conditions, all
concentrations tested were non-cytotoxic (Fig. 1A). Instead, bLf tended
to enhance cell viability, leading to an almost 10% increase in cell
viability at a concentration of 1 mg/mL compared to the control.
Dose-dependent effect of bLf on MAYV infection in Vero cells
Because bLf was non-cytotoxic in the range of 0.2–1 mg/mL, we
then assayed the ability of these bLf concentrations to inhibit MAYV
cytopathic effect. Vero cells were incubated with different concentra-
tions of bLf throughout the infection procedure (during and after virus
inoculation), including a pretreatment step for 1 h at 37 1C, and the
effect on virus plaque formation was assessed. Under these experi-
mental conditions, bLf showed a dose-dependent inhibitory activity,
preventing virus infection by approximately 85% at a concentration of
1 mg/mL (Fig. 1B).
Effects of bLf on different stages of MAYV infection in Vero cells
After establishing the inhibitory proﬁle for increasing bLf concen-
trations, we performed a time-of-addition assay to investigate the step
in virus infection that was affected by the protein. Our result showed
that 1 mg/mL bLf was able to inhibit MAYV plaque formation when
added to Vero cells at different time-points during virus infection
(Fig. 2). However, the antiviral effect was more pronounced when bLf
was added during virus inoculation, inhibiting plaque formation by
approximately 85%, and when the proteinwas present throughout the
infection. A slight inhibition of infection was observed when the
protein was present before (approximately 35%) or after (approxi-
mately 30%) virus inoculation. When bLf was added for 1 h after virus
inoculation – to prevent its effects on the entry of newly synthesized
virus particles into neighboring cells – a minimal inhibition of plaque
formation was observed (approximately 25%). These results suggest
that bLf acts primarily on MAYV entry into host cells and, to a lesser
extent, on virus replication and egress.
No signiﬁcant change in virus titer was observed when MAYV
was separately incubated with 1 mg/mL bLf for 1 h at 4 1C,
indicating that the antiviral effect of bLf was not due to virucidal
activity of the protein through direct interactions with the virus
particles (Suppl. Fig. 2).
Inhibition of MAYV entry into Vero cells by bLf
To directly access the effect of bLf on MAYV entry into Vero cells,
we imaged this early event of infection by ﬂuorescence microscopy
using virus particles whose lipid envelopes were labeled with the
lipophilic probe DiD, and compared the efﬁciency of virus entry in the
presence of bLf with that in the absence of the protein. It is important
to highlight that no change in virus titer due to ﬂuorescent labeling
was detected (data not shown). Fifteenminutes after virus inoculation,
we could observe several ﬂuorescent signals in the cells that were not
exposed to bLf, while only a few ﬂuorescent spots were observed in
the cells that were exposed to 1 mg/mL bLf during virus inoculation
(Fig. 3A). As expected, mock-infected cells showed no ﬂuorescent
signal. By counting the number of ﬂuorescent spots in individual cells,
we determined that bLf inhibited virus entry by approximately 60%
(Fig. 3B).
Fig. 1. Cytotoxicity and antiviral activity of bLf. (A) Vero cell monolayers were
treated with the indicated concentrations of bLf for 48 h at 37 1C or incubated with
culture medium as a control and then subjected to an MTT reduction assay to
determine cell viability. (B) Vero cell monolayers were pretreated with bLf at the
indicated concentrations for 1 h at 37 1C and then inoculated with MAYV under the
same MOI. The bLf protein was maintained at the same pretreatment concentra-
tions during and after the virus inoculation step. After 48 h of infection, cells were
stained, and the virus plaques were counted to determine the efﬁciency of
infection.
Fig. 2. Anti-MAYV effect of bLf on different stages of the infectious cycle.
Monolayers of Vero cells infected with MAYV under the same MOI were treated
with 1 mg/mL bLf at different phases of infection: (A) before virus inoculation,
(B) during virus inoculation, (C) after virus inoculation for 1 h, (D) after virus
inoculation for 48 h and (E) throughout infection. After 48 h of infection, cells were
stained, and the virus plaques were counted to determine the efﬁciency of
infection.
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Role of GAG sulfation in bLf binding to the surface of Vero cells
Due to its positive net charge, bLf is likely to interact with the
sulfate groups of GAGs on the cell surface, and this could be the
mechanism underlying the observed interference with MAYV
entry. To test this hypothesis, we ﬁrst checked whether the ability
of MAYV to infect Vero cells is dependent on the sulfate groups of
GAGs. Using NaClO3, a speciﬁc inhibitor of GAG sulfation, we
Fig. 3. Effect of bLf on MAYV entry into host cells. (A) Subconﬂuent Vero cells were inoculated with DiD-labeled MAYV at an MOI of 10 in the presence (þbLf) or absence
(bLf) of 1 mg/mL bLf. Infection was synchronized by allowing virus binding to the cells for 15 min at 4 1C, and then cells were incubated at 37 1C to allow the infection to
progress. At 15 min post-heating, the samples were ﬁxed and visualized by ﬂuorescence microscopy. The images of individual cells are representative of their respective
visual ﬁelds. Mock: uninfected cells. (B) Fluorescent spots in 10 random cells from each experimental condition above were counted, and the data were expressed as the
dispersion and mean of the number of ﬂuorescent spots per cell.
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aimed to exchange cell surface GAGs for non-sulfated versions, and
observed that cell treatment with the compound for 24 h prior to
infection inhibited virus plaque formation by 65% (Suppl. Fig. 3).
We next assayed whether binding of bLf to the cell surface
would also be affected by inhibition of GAG sulfation. For this
experiment, FITC-labeled bLf molecules were allowed to bind to
control or NaClO3-treated Vero cells, and the ﬂuorescent signals
were imaged by ﬂuorescence microscopy. We found that treat-
ment of Vero cells with NaClO3 dramatically prevented the
interaction of bLf with the plasma membrane (Fig. 4).
Discussion
In this study, we investigated the activity of bLf against MAYV
infection in Vero cells. Our results showed that bLf provides a
strong antiviral activity on MAYV infection, acting primarily on
events leading to virus entry into the cell. This is the ﬁrst study
showing the efﬁcient prevention of MAYV infection by a natural
non-cytotoxic molecule. In this study we tested bLf only in its apo
form. There is a striking number of studies in the literature
showing that the iron saturation of lactoferrin does not play an
important role in its antiviral effect. However, apolactoferrin
remains more potent than its metal-saturated isoforms against
some virus species (Van der Strate et al., 2001). Moreover,
apolactoferrin has a 600 times higher selectivity index, due to its
lack of toxicity (Superti et al., 1997).
Regarding its effects on Vero cells, we observed that bLf
promoted a slight increase in cell viability that has to be further
investigated. Indeed, it has previously been shown that bLf can
sustain cell survival by protecting some cell lineages from apop-
tosis (Grey et al., 2006; Huang et al., 2008; Pietrantoni et al., 2010;
Tang et al., 2010; Francis et al., 2011; Jiang and Lönnerdal, 2012).
Thus, we speculate that the observed increase in viability pro-
moted by bLf could be due to a reduction in cell death by apoptosis
that occurs as a consequence of stress from cell conﬂuence in
culture.
Our results, showing that bLf prevents infection of the host cell
rather than inhibiting virus replication after the target cell
becomes infected, are in accordance with the mode of action of
bLf previously shown for other alpha and unrelated viruses
(Waarts et al., 2005; Van der Strate et al., 2001). Because we
Fig. 4. Requirement for sulfated GAGs for bLf binding to the cell surface. Subconﬂuent Vero cells previously cultured in the presence (þNaClO3) or absence (NaClO3) of
50 mM NaClO3 for 24 h were incubated with 1 mg/mL FITC-labeled bLf in PBS (þbLf) or with PBS alone (bLf) for 15 min at 4 1C. Following incubation, samples were ﬁxed
and visualized by ﬂuorescence microscopy. The images of cell clusters are representative of their respective visual ﬁelds.
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excluded the possibility of bLf directly binding to virus particles,
bLf could prevent MAYV infection of the host cell by either
interfering with the docking of virus to cells by binding to cell
surface proteoglycans or by directly binding to viral receptors on
the host cell that the virus uses for cell entry. Our observation that
binding of bLf to the cell surface is dependent on the presence of
sulfated GAGs on the plasma membrane suggests that the inhibi-
tion of virus entry promoted by the bLf protein is primarily due to
its interaction with the sulfate groups of these molecules. The
blockage of GAGs by bLf would impair their use by virus particles
as initial adhesion molecules. Because the speciﬁc receptor for
Mayaro virus remains unknown, we were unable to test whether
its interaction with bLf may also play a role in the inhibition of
virus entry promoted by the protein.
Because MAYV urbanization is imminent and the virus has a
real potential to adapt to new vectors and spread to non-endemic
areas (Receveur et al., 2010; Hassing et al., 2010; Long et al., 2011;
Neumayr et al., 2012), the ﬁndings of this study, highlighting the
antiviral activity of bLf, are of utmost importance and may
contribute to the development of an effective strategy against
MAYV infection, which is one of the major emerging diseases in
the neotropics (Vasconcelos et al., 2001).
Materials and methods
Virus and cell cultures
MAYV (VR-1277) was obtained from the American Type Culture
Collection (Manassas, VA, USA). Baby hamster kidney (BHK-21)
and African green monkey kidney (Vero) cells were cultured as
monolayers at 37 1C in a humidiﬁed atmosphere with 5% CO2 in
DMEM (Sigma-Aldrich, St. Louis, MO, USA) supplemented with
10% fetal bovine serum (Cultilab, Campinas, SP, Brazil) and 5 mg/mL
gentamicin sulfate (Invitrogen, Carlsbad, CA, USA).
Virus propagation and puriﬁcation
MAYV was propagated and puriﬁed as previously described
(Mezencio and Rebello, 1993) with several modiﬁcations. After
propagation in BHK-21 cells under an MOI of 0.1 for 48 h, the
culture supernatant was collected and cleared of cell debris by
centrifuging at 8000 rpm for 20 min at 4 1C in an RPR 12-2 rotor
(Hitachi, Tokyo, Japan). The supernatant was applied to a 30%
sucrose cushion and centrifuged in a Type 45 Ti rotor (Beckman
Coulter, Brea, CA, USA) at 32,000 rpm for 1 h 40 min at 4 1C. The
pellet was suspended in PBS, layered onto a discontinuous 5–50%
sucrose density gradient and centrifuged at 30,000 rpm for 1 h
30 min at 4 1C in an SW 40 Ti rotor (Beckman Coulter). Fractions
were collected, and the fraction containing the virus was identiﬁed
by reading the optical density at 260 and 280 nm. Puriﬁed virions
were aliquoted and stored at 80 1C until further use.
BLf preparation
Apolactoferrin from bovine whey (Life Extension, Fort Lauder-
dale, FL, USA) was dissolved to a concentration of 100 mg/mL in
PBS and centrifuged at 6000 rpm for 5 min at 4 1C to remove the
cellulose excipient. The supernatant was passed through a 0.22-
mm syringe-driven ﬁlter unit (Millipore, Billerica, MA, USA),
aliquoted and stored as a stock solution at 20 1C until further
use. This procedure eliminated all excipients described in the
formulation provided by the manufacturer. Protein purity was 95%,
as stated by the manufacturer and conﬁrmed by SDS-PAGE (Suppl.
Fig. 1).
Fluorescent labeling of virus particles and bLf
Approximately 1010 MAYV particles were incubated with
2 nmol of DiD (Molecular Probes, Eugene, OR, USA) in PBS for
10 min at room temperature. The unincorporated dye was
removed by centrifuging through an Amicon Ultra ﬁlter unit with
a 100-kDa molecular weight cut-off (Millipore). Labeled virus
particles were suspended in PBS, passed through a syringe-
driven ﬁlter unit with 0.22-mm pore size to remove virus aggre-
gates and immediately used for experiments. DiD labeling was
conﬁrmed by scanning the light absorption spectrum of the virus
sample.
BLf was incubated with FITC (Molecular Probes) at a molar ratio
of 1:10 in basic phosphate buffer (2.5% Na2HPO4 7H2O and 0.082%
NaH2PO4, pH 8.0) for 1 h at 4 1C. The unincorporated dye was
removed by centrifuging through an Amicon Ultra ﬁlter unit with
a 30-kDa molecular weight cut-off (Millipore). Labeled protein
molecules were suspended in PBS, passed through a syringe-
driven ﬁlter unit with 0.22-mm pore size and immediately used
for experiments. FITC labeling was conﬁrmed by subjecting the
protein sample to SDS-PAGE followed by the ultraviolet transillu-
mination of the gel.
Cytotoxicity assay
Vero cell monolayers seeded in 96-well plates (TPP, Trasadin-
gen, Switzerland) were incubated with different concentrations of
bLf at 37 1C for 48 h and then assayed for MTT reduction as
previously described (Mosmann, 1983).
Antiviral assays
All assays for assessing the activity of bLf against MAYV
infection were conducted in Vero cell monolayers seeded in 12-
well plates (TPP). The dose–response activity of bLf was evaluated
by incubating cells with the indicated concentrations of the
protein at 37 1C throughout the course of infection, including
immediately before (for 1 h), during (for 1 h) and immediately
after (for 48 h) virus inoculation, at a density of 100 PFUs per well.
For the time-of-addition assays, the experimental procedure was
the same, except bLf was present at a single concentration (1 mg/
mL) separately for each stage of infection, in addition to immedi-
ately after virus inoculation for 1 h and the remainder of the
infection. At 48 h post-infection, cells were stained with 1% crystal
violet, and the virus plaques were counted to determine the
efﬁciency of infection.
Imaging of virus entry and bLf binding
Subconﬂuent Vero cells seeded in 35-mm glass-bottom dishes
(MatTek, Ashland, MA, USA) were used for both imaging proce-
dures. To image virus entry, cells were incubated with DiD-labeled
MAYV under an MOI of 10 for 15 min at 4 1C in the presence or
absence of 1 mg/mL bLf. After this virus binding synchronization
step, unbound virus particles were washed away with PBS, and
cells were incubated in DMEM supplemented with 2% fetal bovine
serum and 5 mg/mL gentamicin sulfate at 37 1C to allow for virus
entry. At 15 min post-heating, cells were washed again with PBS
and ﬁxed with 3.7% formaldehyde for 15 min. To image bLf
binding, cells previously cultured in the presence or absence of
50 mM NaClO3 for 24 h were incubated with FITC-labeled bLf for
15 min at 4 1C, washed with PBS to remove unbound bLf molecules
and ﬁxed as above. Samples were visualized on an LSM 510 META
laser-scanning confocal ﬂuorescence microscope (Carl Zeiss, Ober-
kochen, Germany) with excitation by a helium-neon laser at
633 nm and emission collected from 650 to 710 nm for imaging
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DiD-labeled MAYV or with excitation by an argon ion laser at
488 nm and emission collected from 500 to 550 nm for imaging
FITC-labeled bLf.
Statistical analyses
Statistical analyses were performed using an unpaired t-test
with a two-tailed P-value and a one-way ANOVA with the
Dunnett's post-test. Data were expressed as the mean7SD, and
P-values less than 0.05 were considered statistically signiﬁcant.
Given these criteria, all differences observed were signiﬁcant,
except when otherwise stated.
Acknowledgments
We thank Emerson R. Gonçalves and Vivian N.S. Ferreira for
competent technical assistance. This work was supported by
Grants from Coordenação de Aperfeiçoamento de Pessoal de Nível
Superior (CAPES), Conselho Nacional de Desenvolvimento Cientí-
ﬁco e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do
Estado do Rio de Janeiro (FAPERJ), Financiadora de Estudos e
Projetos (FINEP), Instituto Nacional de Ciência e Tecnologia de
Biologia Estrutural e Bioimagem (INBEB) and Programa de Apoio a
Núcleos de Excelência (PRONEX).
Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2014.01.022.
References
Anderson, C.R., Downs, W.G., Wattley, G.H., Ahin, N.W., Reese, A.A., 1957. Mayaro
virus: a new human disease agent. II. Isolation from blood of patients in
Trinidad, B.W.I. Am. J. Trop. Med. Hyg. 6, 1012–1016.
Casals, J., Whitman, L., 1957. Mayaro virus: a new human disease agent. I.
Relationship to other arbor viruses. Am. J. Trop. Med. Hyg. 6, 1004–1011.
Francis, N., Wong, S.H., Hampson, P., Wang, K., Young, S.P., Deigner, H.P., Salmon, M.,
Scheel-Toellner, D., Lord, J.M., 2011. Lactoferrin inhibits neutrophil apoptosis via
blockade of proximal apoptotic signaling events. Biochim. Biophys. Acta 1813,
1822–1826.
Grey, A., Zhu, Q., Watson, M., Callon, K., Cornish, J., 2006. Lactoferrin potently
inhibits osteoblast apoptosis, via an LRP1-independent pathway. Mol. Cell
Endocrinol. 251, 96–102.
Hassing, R.J., Leparc-Goffart, I., Blank, S.N., Thevarayan, S., Tolou, H., van Doornum,
G., van Genderen, P.J., 2010. Imported Mayaro virus infection in the Nether-
lands. J. Infect. 61, 343–345.
Huang, N., Bethell, D., Card, C., Cornish, J., Marchbank, T., Wyatt, D., Mabery, K.,
Playford, R., 2008. Bioactive recombinant human lactoferrin, derived from rice,
stimulates mammalian cell growth. In Vitro Cell. Dev. Biol. Anim. 44, 464–471.
Jenssen, H., Hancock, R.E., 2009. Antimicrobial properties of lactoferrin. Biochimie
91, 19–29.
Jiang, R., Lönnerdal, B., 2012. Apo- and holo-lactoferrin stimulate proliferation of
mouse crypt cells but through different cellular signaling pathways. Int. J.
Biochem. Cell Biol. 44, 91–100.
Long, K.C., Ziegler, S.A., Thangamani, S., Hausser, N.L., Kochel, T.J., Higgs, S., Tesh, R.
B., 2011. Experimental transmission of Mayaro virus by Aedes aegypti. Am. J.
Trop. Med. Hyg. 85, 750–757.
Metz-Boutigue, M.H., Jollès, J., Mazurier, J., Schoentgen, F., Legrand, D., Spik, G.,
Montreuil, J., Jollès, P., 1984. Human lactotransferrin: amino acid sequence and
structural comparisons with other transferrins. Eur. J. Biochem. 145, 659–676.
Mezencio, J.M., Rebello, M.A., 1993. Mayaro virus proteins. Mem. Inst. Oswaldo Cruz
88, 299–304.
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65,
55–63.
Mourão, M.P., Bastos, M.S., de Figueiredo, R.P., Gimaque, J.B., Galusso, E.S., Kramer,
V.M., de Oliveira, C.M., Naveca, F.G., Figueiredo, L.T., 2012. Mayaro fever in the
city of Manaus, Brazil, 2007–2008. Vector Borne Zoonotic Dis. 12, 42–46.
Neumayr, A., Gabriel, M., Fritz, J., Günther, S., Hatz, C., Schmidt-Chanasit, J., Blum, J.,
2012. Mayaro virus infection in traveler returning from Amazon Basin, northern
Peru. Emerg. Infect. Dis. 18, 695–696.
Pietrantoni, A., Dofrelli, E., Tinari, A., Ammendolia, M.G., Puzelli, S., Fabiani, C.,
Donatelli, I., Superti, F., 2010. Bovine lactoferrin inhibits inﬂuenza A virus
induced programmed cell death in vitro. Biometals 23, 465–475.
Pinheiro, F.P., Freitas, R.B., Travassos da Rosa, J.F., Gabbay, Y.B., Mello, W.A., LeDuc, J.
W., 1981. An outbreak of Mayaro virus disease in Belterra, Brazil. I. Clinical and
virological ﬁndings. Am. J. Trop. Med. Hyg. 30, 674–681.
Receveur, M.C., Grandadam, M., Pistone, T., Malvy, D., 2010. Infection with Mayaro
virus in a French traveller returning from the Amazon region, Brazil, January,
2010. Euro Surveill. 15, 19563.
Superti, F., Ammendolia, M.G., Valenti, P., Seganti, L., 1997. Antirotaviral activity of
milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell
line HT-29. Med. Microbiol. Immunol. 186, 83–91.
Tang, L., Cui, T., Wu, J.J., Liu-Mares, W., Huang, N., Li, J., 2010. A rice-derived
recombinant human lactoferrin stimulates ﬁbroblast proliferation, migration,
and sustains cell survival. Wound Repair Regen. 18, 123–131.
Tomita, M., Wakabayashi, H., Shin, K., Yamauchi, K., Yaeshima, T., Iwatsuki, K., 2009.
Twenty-ﬁve years of research on bovine lactoferrin applications. Biochimie 91,
52–57.
Van der Strate, B.W., Beljaars, L., Molema, G., Harmsen, M.C., Meijer, D.K., 2001.
Antiviral activities of lactoferrin. Antivir. Res. 52, 225–239.
Vasconcelos, P.F., Travassos da Rosa, A.P., Rodrigues, S.G., Travassos da Rosa, E.S.,
Dégallier, N., Travassos da Rosa, J.F., 2001. Inadequate management of natural
ecosystem in the Brazilian Amazon region results in the emergence and
reemergence of arboviruses. Cad. Saúde Pública 17, 155–164.
Waarts, B.L., Aneke, O.J., Smit, J.M., Kimata, K., Bittman, R., Meijer, D.K., Wilschut, J.,
2005. Antiviral activity of human lactoferrin: inhibition of alphavirus interac-
tion with heparan sulfate. Virology 333, 284–292.
C.A.M. Carvalho et al. / Virology 452-453 (2014) 297–302302
